Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Ip A, Petrillo A, Della Pia A, Lee GG, Gill S, Varughese T, Zenreich J, Gutierrez M, Zhang J, Ahn J, Bharani V, Nejad AS, Pascual L, Feldman TA, Leslie LA, Goy AH.
Ip A, et al. Among authors: lee gg.
Leuk Lymphoma. 2023 Dec;64(14):2225-2235. doi: 10.1080/10428194.2023.2259528. Epub 2023 Dec 25.
Leuk Lymphoma. 2023.
PMID: 37740588
Clinical Trial.